Navigation Links
PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
Date:7/26/2013

LONDON and CAMBRIDGE, England, July 26, 2013 /PRNewswire/ --

PolyTherics receives new investment to accelerate growth

PolyTherics Limited ("PolyTherics") announces that it has merged with Antitope Limited ("Antitope"), the leading provider of antibody engineering and immunogenicity screening services, to create an enlarged group with an extensive suite of services and technologies to enable the development of better biopharmaceuticals.

PolyTherics is issuing new shares up to an aggregate value of £13.5 million to fund the merger with Antitope and to provide working capital for the enlarged group. Imperial Innovations (AIM: IVO) led the investment and brought in new investor Invesco Perpetual with further funds provided by Mercia Fund Management and Advantage Enterprise & Innovation Fund.

The enlarged PolyTherics group will leverage its combined portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. The combined portfolio will include conjugation technologies to produce more stable and homogeneous antibody drug conjugates, technologies to optimise the pharmacokinetics of biologics, technologies for immunogenicity screening, technologies to re-engineer antibodies and proteins to reduce their immunogenicity, and cell line development technologies. The group has a strong client base in the biotechnology and pharmaceutical industry, including many of the world's top companies.

Dr John Burt will continue as CEO of PolyTherics and Antitope will operate as a wholly owned subsidiary of the PolyTherics group. Dr Matthew Baker will continue as Chief Scientific Officer for Antitope and the company will retain its base, management and operational structure at the Babraham Research Campus, near Cambridge.    

The expanded offering will provide the PolyTherics group with a broad technology platform for growth and a solid financial base with sustainable revenue streams over the short-, medium- and longer-term. Growing revenues are derived from the services offered by Antitope and feasibility studies undertaken by PolyTherics and from pre-defined milestone payments under licence agreements for the group's conjugation and de-immunisation technologies. These licences also have the potential to provide future royalties on a portfolio of products which utilise the group's proprietary technologies.

Dr John Burt, CEO of PolyTherics, said: "The combination of PolyTherics and Antitope is a significant strategic step, immediately broadening our business and accelerating our growth. We look forward to building PolyTherics into a leading global provider of technologies that enable the development of better biopharmaceuticals."

Dr Matthew Baker, CEO and CSO of Antitope, said: "The combination of Antitope with PolyTherics provides an excellent opportunity for us to expand and grow our offering to our existing partners. The combined company will have critical mass in terms of technologies, skills and resources and will enable us to leverage the full potential of our antibody engineering and deimmunisation platforms. We are delighted to become part of the PolyTherics group and believe this move will enable us to support growing demand for our technologies from the global biopharma industry."

About PolyTherics

PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development.

PolyTherics' portfolio includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals, including ThioBridge™ for more stable and homogeneous antibody drug conjugates, TheraPEG™, CyPEG™, HiPEG™ and PolyPEG™ for optimisation of the pharmacokinetics of biologics  and GlycoPol™ for targeted delivery.

The PolyTherics group will provide immunogenicity testing, antibody humanisation and protein re-engineering technologies through its Antitope subsidiary, including EpiScreen™, Composite Human Antibody™, Composite Protein™ and Composite CHO™. These technologies have been used to develop several therapeutic antibody candidates that are advancing through clinical trials. The group provides its services and technologies to an international client base that includes many of the world's leading biotechnology and pharmaceutical companies.

PolyTherics is a privately owned UK company backed by institutional investors including Imperial Innovations (AIM: IVO), Invesco Perpetual, Mercia Fund Management, Advantage Enterprise & Innovation Fund (managed by Catapult Venture Partners), ProVen Health, Oxford Technology VCTs and high net worth individual's funds managed by Longbow Capital. The Company has dedicated facilities in London, Cambridge and Coventry, UK.

http://www.polytherics.com

http://www.antitope.co.uk

For more information contact:

John Burt, PolyTherics
Tel.: +44(0)20-7691-3580
Email: john.burt@polytherics.com

Matthew Baker, Antitope
Tel.: +44(0)1223-496190
Email:  matthew.baker@antitope.co.uk

Mark Swallow, Sita Shah, Chris Gardner
Citigate Dewe Rogerson
Tel.: +44(0)20-7282-2948/1052/2995
Email: mark.swallow@citigatedr.co.uk


'/>"/>
SOURCE PolyTherics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shimadzu's New MALDI-7090 TOF-TOF Mass Spectrometer Combines High Throughput, High Resolution and High Energy for the Ultimate in Tandem MS Capabilities
2. FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice
3. Fantastic flash memory combines graphene and molybdenite
4. Motus Brings a Whole New Dimension to the NFL Combine Training Program at IMG Academy
5. New Informatics and Bioimaging Center combines resources, expertise from UMD, UMB
6. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
7. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
8. NYSCF scientists create personalized bone substitutes from skin cells
9. American Management Association Teams With Biogen Idec To Create Life Skills Workshops For People Living With Hemophilia
10. Data Spectacles Create Rosy Tint
11. Leading Biotoxin & Mold Illness Authority Creates Certification Process for Treatment Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 05, 2016 , ... CereScan, the nation’s leader ... Association during National Stroke Awareness Month in May. An infographic created by ... month. CereScan will donate $1 up to a maximum of $3,000 through ...
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , the commercial ... with McGill University . The partnership is designed to advance research in pain ... help patients in pain. With the new agreement, researchers at Proove Biosciences are able ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced ... causes tumors to grow on nerves throughout the body. It affects 1 in 3,000 ... community events held during the month of May, as well as online activities, Neurofibromatosis ...
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to ... , Doug began his career at PBI-Gordon in February 1988, after finishing his ... variety of roles, ranging from customer service to national product manager, to helping develop, ...
Breaking Biology Technology:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/21/2016)... 22, 2016 Unique technology ... for superior security   Xura, ... of secure digital communications services, today announced it is ... offer enterprise customers, particularly those in the Financial Services ... voice authentication within a mobile app, alongside, and in ...
(Date:3/15/2016)... York , March 15, 2016 ... market report published by Transparency Market Research "Digital Door Lock ... and Forecast 2015 - 2023," the global digital door lock ... 731.9 Mn in 2014 and is forecast to grow at ... Growth of micro, small and medium enterprises (MSMEs) across the ...
Breaking Biology News(10 mins):